IFNAR1 and neoplasm: The absence or downregulation of IFNAR can drive the TME into an immunosuppressive microenvironment that protects malignant tumor cells from cytotoxic T lymphocytes (CTLs), resulting in a poor prognosis in cancer patients (17).